Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion
Authors' conclusion
In GH&PRL-PA, the biochemical control achieved with fgSRL as monotherapy is substantially worse than in patients harboring GH-PA, supporting the inclusion of cabergoline as first-line medical treatment in combination with fgSRLs in these subgroups of patients.
Study context
- Population
- Treatment-naive acromegaly patients followed 2003–2023 in 33 tertiary Spanish hospitals with ≥6 months of first-line medical treatment
- Participants
- 144 patients
- Exposure
- Growth hormone (GH)&PRL-PA vs GH-PA: response to first-line medical treatment
- Outcome
- Disease control after first-line medical treatment
- Follow-up
- 6 months
Methodological detailsmulticentre, 33 tertiary Spanish hospitals
- Multicentre
- 33 tertiary Spanish hospitals
Main finding
As reported in the abstract
P = 0.04
Observational data: associations, not effects.
Further findings
Age at baseline · younger with GH&PRL-PA
P < 0.01
Macroadenoma · baseline · more frequent with GH&PRL-PA
P = 0.03
Received combination therapy (fgSRL + cabergoline) · more frequent with GH&PRL-PA
P < 0.01
Disease control under combination first-generation somatostatin receptor ligand (fgSRL) + cabergoline · 6 months
- Differences in disease control between GH&PRL-PA and GH-PA disappeared with combination fgSRL + cabergoline
First-line treatment received (all patients)
- fgSRL monotherapy
- 106 (73.6%)
- fgSRL + cabergoline combination
- 38 (26.4%)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →